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Caladrius Biosciences has recently identified biomarkers
that may predict clinical efficacy in immunotherapy treat-
ments for melanoma. While numerous clinical trials
demonstrated success in long-term survival using immu-
notherapy agents in various types of malignancies, very
few have demonstrated the underlying mechanism of
action of these therapies. Caladrius Biosciences is develop-
ing an innovative approach to cancer treatment targeting
the cells responsible for tumor growth and metastasis,
known as cancer stem cells (CSC) or tumor-initiating cells
(TIC). The therapy (CLBS20, also known as NBS20) uses
purified autologous CSCs, derived from a patient’s own
tumor and grown as a tumor cell line, as the antigen
source of tumor-associated antigens to induce or enhance
an anti-tumoral immune response. Using the immune sys-
tem to target CSCs may provide a complementary or
adjunctive therapy that would result in better long-term
control, and possibly even a cure, of certain cancers. This
approach has shown consistent and compelling results in
sequential open-label and randomized Phase II trials for
advanced stage melanoma, and is now being tested in a
Phase III trial called the Intus Study.
In order to determine whether isolated CSC popula-
tions contained antigenic cancer-related mutations, exo-
mic sequencing was performed on tumor cell lines from
5 distinct melanoma tumors using Illumina’s sequencing
technology. Sequencing results, combined with epige-
netic data, indicated the presence of cancer and metas-
tasis-related driver mutations with highly antigenic
properties. Identification of these mutated antigens
allows us to further study specific T cell activation using
mixed lymphocyte reaction assays. Concurrently, we
analyzed patient serum samples before and 1 week after
3 weekly injections of CLBS20, using comprehensive
high-throughput screening for proteins responsible for
immune response, inflammation and angiogenesis. This
approach allows us to look into mechanisms of immu-
nosuppression by which tumor cells circumvent native
and adaptive immune responses. The analysis of cyto-
kines demonstrated a decrease of serum tumor markers
and the reduction of Treg response in the treatment
arm, compared to the control arm, and the results sug-
gest a combination of humoral and cell immune
responses. A set of biomarkers associated with poor
response in the treatment arm was identified. This dis-
covery demonstrates a complex immune response fol-
lowing administration of CLBS20 immunotherapy and is
of critical importance for effective prediction of patient
response to therapy.
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